Axial Spondyloarthritis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Axial Spondyloarthritis pipeline constitutes 10+ key companies continuously working towards developing 12+ Axial Spondyloarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Axial Spondyloarthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Axial Spondyloarthritis Market.

The Axial Spondyloarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Axial Spondyloarthritis Pipeline Report: https://www.delveinsight.com/sample-request/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Axial Spondyloarthritis treatment therapies with a considerable amount of success over the years.
• Axial Spondyloarthritis companies working in the treatment market are Galapagos NV, Sinocelltech, Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others, are developing therapies for the Axial Spondyloarthritis treatment
• Emerging Axial Spondyloarthritis therapies in the different phases of clinical trials are- Filgotinib, SCT650C, SIMPONI (golimumab), XELJANZ (tofacitinib), Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others are expected to have a significant impact on the Axial Spondyloarthritis market in the coming years.
• In January 2025, MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company developing advanced therapies for inflammatory diseases, announced that patient screening has begun for three new trials evaluating sonelokimab, an investigational Nanobody® therapy. These trials expand the clinical program to include adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA), alongside existing studies in adult patients with HS and active psoriatic arthritis (PsA).
• In November 2024, UCB, a global biopharmaceutical company, announced new two-year data demonstrating a sustained clinical response for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, in adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS). These findings come from the Phase 3 studies BE OPTIMAL (PsA), BE COMPLETE (PsA), and their open-label extension BE VITAL, as well as BE MOBILE 1 (nr-axSpA), BE MOBILE 2 (AS), and their open-label extension BE MOVING.
• In September 2024, UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for three indications: the treatment of adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS). BIMZELX is the first treatment approved for all three conditions, designed to selectively inhibit two key cytokines involved in inflammation-interleukin 17A (IL-17A) and interleukin 17F (IL-17F). These approvals follow its initial U.S. approval in October 2023 for moderate-to-severe plaque psoriasis in adults eligible for systemic therapy or phototherapy.
• DelveInsight estimates that the total prevalent population of axial spondyloarthritis in the 7MM was about 4,575,000 in 2023, and this number is projected to rise significantly throughout the study period from 2020 to 2034.

Axial Spondyloarthritis Overview
Axial spondyloarthritis (axSpA) is a chronic inflammatory arthritis that primarily affects the spine and sacroiliac joints (where the spine connects to the pelvis). It causes back pain, stiffness, and reduced mobility, especially in the lower back and hips. The condition can be classified into two type -radiographic axSpA (ankylosing spondylitis), where structural changes are visible on X-rays, and non-radiographic axSpA, where inflammation is seen only through MRI or lab tests. Early diagnosis and treatment are important to prevent joint damage and maintain mobility.

Get a Free Sample PDF Report to know more about Axial Spondyloarthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Axial Spondyloarthritis Drugs Under Different Phases of Clinical Development Include:
• Filgotinib: Galapagos NV
• SCT650C: Sinocelltech
• SIMPONI (golimumab): Janssen Pharmaceuticals
• XELJANZ (tofacitinib): Pfizer
• Bimekizumab: UCB Biopharma
• CC-99677: Celgene
• ABY- 035: Inmagene Biopharmaceuticals
• Filgotinib: Galapagos NV
• KHK4827: Kyowa Kirin Co., Ltd.
• Ixekizumab: Eli Lilly and Company
• Golimumab: Merck Sharp & Dohme LLC
• etanercept: Pfizer
• Bimekizumab: UCB Biopharma
• Secukinumab: Novartis
• SHR0302: Jiangsu HengRui Medicine
• Certolizumab Pegol: UCB Biopharma

Axial Spondyloarthritis Route of Administration
Axial Spondyloarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Axial Spondyloarthritis Molecule Type
Axial Spondyloarthritis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Axial Spondyloarthritis Pipeline Therapeutics Assessment
• Axial Spondyloarthritis Assessment by Product Type
• Axial Spondyloarthritis By Stage and Product Type
• Axial Spondyloarthritis Assessment by Route of Administration
• Axial Spondyloarthritis By Stage and Route of Administration
• Axial Spondyloarthritis Assessment by Molecule Type
• Axial Spondyloarthritis by Stage and Molecule Type

DelveInsight's Axial Spondyloarthritis Report covers around 12+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Axial Spondyloarthritis product details are provided in the report. Download the Axial Spondyloarthritis pipeline report to learn more about the emerging Axial Spondyloarthritis therapies at:
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Axial Spondyloarthritis Therapeutics Market include:
Key companies developing therapies for Axial Spondyloarthritis are - Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly, Kyowa Kirin, Key companies driving axSpA research and development include UCB, AbbVie, Pfizer, Celgene, Inmagene Biopharmaceuticals, and others.

Axial Spondyloarthritis Pipeline Analysis:
The Axial Spondyloarthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Axial Spondyloarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Axial Spondyloarthritis Treatment.
• Axial Spondyloarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Axial Spondyloarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Axial Spondyloarthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Axial Spondyloarthritis drugs and therapies-
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Axial Spondyloarthritis Pipeline Market Drivers
• Increasing prevalence and early diagnosis of axial spondyloarthritis (axSpA) are driving the demand for novel and effective therapies.
• Growing focus on biologic and targeted synthetic drugs (e.g., IL-17 and JAK inhibitors) is enhancing treatment options and fueling pipeline growth.
• Rising investments in R&D activities and collaborations between pharma companies and research institutions are accelerating drug development.
• Enhanced understanding of disease mechanisms and biomarkers is enabling precision medicine approaches.

Axial Spondyloarthritis Pipeline Market Barriers
• High development costs and long timelines associated with biologics and advanced therapies pose major challenges.
• Stringent regulatory requirements and complex clinical trial designs slow down approval processes.
• Limited patient awareness and misdiagnosis often delay treatment initiation, reducing potential patient pools.
• Patent expirations and growing biosimilar competition can impact profitability and market exclusivity.

Scope of Axial Spondyloarthritis Pipeline Drug Insight
• Coverage: Global
• Key Axial Spondyloarthritis Companies: Galapagos NV, Sinocelltech, Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others
• Key Axial Spondyloarthritis Therapies: Filgotinib, SCT650C, SIMPONI (golimumab), XELJANZ (tofacitinib), Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others
• Axial Spondyloarthritis Therapeutic Assessment: Axial Spondyloarthritis current marketed and Axial Spondyloarthritis emerging therapies
• Axial Spondyloarthritis Market Dynamics: Axial Spondyloarthritis market drivers and Axial Spondyloarthritis market barriers

Request for Sample PDF Report for Axial Spondyloarthritis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.